Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia

3 Sept 2020

Abstract excerpt

Allogeneic hematopoietic cell transplantation (alloHCT) can cure previously treated high-risk chronic lymphocytic leukemia (CLL) patients if they are suitable for transplant through the graft-versus-leukemia effect. However, since the emergence of targeted therapies, the role of alloHCT for high-risk CLL is less clear. To address this question, we evaluated 108 high-risk CLL patients who underwent alloHCT from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32882002
DOI: 10.1182/bloodadvances.2020002184

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemiaPMID 32882002Read ↗

Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20‐year cohortSemantic proximity Read ↗

Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic StrategiesSemantic proximity Read ↗

New insights into hematopoietic stem cell transplantation for chronic lymphocytic leukemia: a 2015 perspective.Semantic proximity Read ↗

Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies.Semantic proximity Read ↗

TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.Semantic proximity Read ↗

[Chronic lymphocytic leukemia : treatment concepts in transition].Semantic proximity Read ↗

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapiesSemantic proximity Read ↗

Update on therapy of chronic lymphocytic leukemia.Semantic proximity Read ↗

Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single centerSemantic proximity Read ↗

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?Semantic proximity Read ↗

Optimized Xenograft Protocol for Chronic Lymphocytic Leukemia Results in High Engraftment Efficiency for All CLL Subgroups.Semantic proximity Read ↗

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.